112 related articles for article (PubMed ID: 15337242)
1. The molecular determinants of estrogen receptor pharmacology.
McDonnell DP
Maturitas; 2004 Aug; 48 Suppl 1():S7-12. PubMed ID: 15337242
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre M; Smith CL
J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanism of tissue-specific actions of sex steroid hormones and SERM for bone remodeling].
Kato S
Clin Calcium; 2005 May; 15(5):825-30. PubMed ID: 15876746
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
6. [Estrogen receptor subtypes and the regulatory effect of receptor ligand binding on gene transcription].
An SJ; Zhang YX
Sheng Li Ke Xue Jin Zhan; 2002 Oct; 33(4):309-12. PubMed ID: 12650065
[TBL] [Abstract][Full Text] [Related]
7. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
Mukherjee S; Saha A; Roy K
Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
[TBL] [Abstract][Full Text] [Related]
9. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
Nilsson S; Koehler KF
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in estrogen receptor modulators.
Henke BR; Heyer D
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):437-48. PubMed ID: 16022180
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer, estrogen receptor and ligands.
Bai Z; Gust R
Arch Pharm (Weinheim); 2009 Mar; 342(3):133-49. PubMed ID: 19274700
[TBL] [Abstract][Full Text] [Related]
14. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.
Richardson TI; Norman BH; Lugar CW; Jones SA; Wang Y; Durbin JD; Krishnan V; Dodge JA
Bioorg Med Chem Lett; 2007 Jul; 17(13):3570-4. PubMed ID: 17485205
[TBL] [Abstract][Full Text] [Related]
15. Agonist activity of the 3-hydroxy metabolites of tibolone through the oestrogen receptor in the mouse N20.1 oligodendrocyte cell line and normal human astrocytes.
Guzmán CB; Zhao C; Deighton-Collins S; Kleerekoper M; Benjamins JA; Skafar DF
J Neuroendocrinol; 2007 Dec; 19(12):958-65. PubMed ID: 18001325
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.
Jordan VC
J Med Chem; 2003 Mar; 46(6):883-908. PubMed ID: 12620065
[No Abstract] [Full Text] [Related]
17. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
Kurbel S
Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
[TBL] [Abstract][Full Text] [Related]
18. Estrogens and SERMs in coronary heart disease.
Regitz-Zagrosek V; Wintermantel TM; Schubert C
Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
[TBL] [Abstract][Full Text] [Related]
19. Signaling by estrogens.
Cheskis BJ; Greger JG; Nagpal S; Freedman LP
J Cell Physiol; 2007 Dec; 213(3):610-7. PubMed ID: 17886255
[TBL] [Abstract][Full Text] [Related]
20. [Selective estrogen receptor modulators: mechanisms of action and their tissue selectivity].
Azuma K; Inoue S
Clin Calcium; 2004 Oct; 14(10):12-26. PubMed ID: 15577127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
